Alamar Biosciences, Inc.
Alamar Biosciences, Inc. develops and commercializes proteomics and immunoassay instruments, consumables, and related services for life-science research. Its core platform includes the ARGO HT instrument, NULISA assay consumables, and TAP services, with sales primarily in North America, Europe, and Asia through direct and distribution channels.
Business
Share of revenueBenchtop analytical instruments used for proteomics and immunoassay workflows.
Assay consumables and kits used on installed instruments for recurring testing.
TAP Services, analytical testing, and maintenance/repair contracts.
Customers
Customers are primarily academic and research institutions, biopharmaceutical companies, contract research organizations, and service laboratories. These buyers use Alamar’s platform for biomarker discovery, assay development, and research workflows that require sensitive multiplexed protein analysis.
Universities and research centers buy instruments, consumables, and TAP Services for basic and translational research.
Drug developers use the platform for biomarker discovery, assay validation, and preclinical research.
CROs purchase services and systems to support outsourced analytical programs for pharma and biotech clients.
Labs buy instruments and consumables to offer testing and analytical services to third parties.
Channel partners resell products in selected international markets where direct coverage is limited.
Strategy
The company is expanding its installed base by broadening sales coverage, adding new instruments, and improving the applications around its proteomics platform. It is also investing in future products, including ARGO HT/DX, to extend the platform from research use toward translational and diagnostic markets if regulatory approvals are obtained.
A larger installed base increases recurring consumables demand and service revenue.
More applications and improved performance support adoption and customer retention.
Future regulated products could expand the addressable market beyond RUO research use.
Geography
Q2/2026Alamar sells primarily through direct channels in North America, Europe, and China, with additional distribution coverage in Australia, parts of Eastern Europe, India, Japan, Singapore, and South Korea. In the reported quarter, the Americas contributed 62% of sales, EMEA 29%, and APAC 9%, reflecting a business that is still anchored in U.S. research demand but increasingly international.
Share of the revenue the company reports by geography.
Risks
The business depends on a small number of specialized suppliers and on customer funding cycles, so supply interruptions or grant-driven demand swings can materially affect sales timing. It also faces regulatory and execution risk as it develops products intended for diagnostic use, while international operations add foreign exchange and trade-related exposure.
- Single-source supply dependenceImpact: HighLikelihood: Medium
A majority of key antibodies and some instrument components come from single suppliers, creating shortage risk.
Exposure: NULISA assay antibodies and instrument/consumable components
- Regulatory transition riskImpact: HighLikelihood: Medium
If products are viewed as clinical diagnostics, marketing authorization could be required before sale.
Exposure: ARGO HT/DX and any future diagnostic applications
- Customer funding and seasonalityImpact: MediumLikelihood: Medium
Many customers rely on government grants and year-end budgets, which can shift purchase timing.
Exposure: Instrument and consumables orders
- Trade and logistics disruptionImpact: MediumLikelihood: Medium
Tariffs, shipping delays, and labor shortages can disrupt supply and customer delivery.
Exposure: Global manufacturing and distribution network
- Foreign exchange volatilityImpact: MediumLikelihood: Low
A portion of revenue is denominated in euros and other foreign currencies, affecting reported results.
Exposure: Europe and other international markets
Accounting
Judgemental itemsDifferent recognition timing for instruments, consumables, services, and maintenance affects quarterly revenue mix.
Impact: Can create quarter-to-quarter volatility in reported sales
Customer budget cycles and grant funding can shift purchases toward year-end.
Impact: Makes first-quarter and fourth-quarter results less comparable
Manufacturing and product launch risk can require provisions for obsolete stock and warranty claims.
Impact: Affects gross margin and cost of revenue
Remeasurement of convertible notes can create non-cash gains or losses.
Impact: Can add volatility below operating income
International sales, especially euro-denominated revenue, create translation and transaction effects.
Impact: Can affect revenue, expenses, and other income/expense
Similar listed companies
Publicly listed companies with a comparable business focus.
Alumis Inc
ALMS · Pharmaceutical Preparations
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Nautilus Biotechnology, Inc.
NAUT · Laboratory Analytical Instruments
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Alector, Inc.
ALEC · Biological Products, (No Diagnostic Substances)
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Last updated: 24/09/2026